Jaguar Health (JAGX) Cash from Financing Activities (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Cash from Financing Activities of -$6.6 million for Q1 2026, down 233.21% year-over-year from $5.0 million in Q1 2025, and down 167.57% quarter-over-quarter from $9.8 million in Q4 2025.
Jaguar Health (JAGX) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Cash from Financing Activities for 13 consecutive years, with -$6.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 233.21% year-over-year to -$6.6 million; the TTM figure through Mar 2026 stood at $12.1 million (down 49.42% YoY), while the FY2025 annual figure was $23.7 million, down 24.14% from the prior year.
- Cash from Financing Activities eased to -$6.6 million in Q1 2026 per JAGX's latest filing, from $9.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $18.8 million in Q1 2023 and bottomed at -$6.6 million in Q1 2026.
- Historically, Cash from Financing Activities has averaged $6.2 million across 5 years, with a median of $5.0 million in 2025.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 2620.38% — and 2026, when it tumbled 233.21%.
- Jaguar Health's Cash from Financing Activities stood at $1.6 million in 2022, then jumped by 550.18% to $10.6 million in 2023, then plunged by 73.43% to $2.8 million in 2024, then jumped by 245.94% to $9.8 million in 2025, then sank by 167.57% to -$6.6 million in 2026.
- Business Quant data shows JAGX's Cash from Financing Activities at -$6.6 million in Q1 2026, $9.8 million in Q4 2025, and $6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | -6.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.62 Mn |
| Mar 31, 2026 | -6.62 Mn |
| Dec 31, 2025 | 9.79 Mn |
| Dec 31, 2025 | 9.79 Mn |
| Sep 30, 2025 | 6.26 Mn |
| Sep 30, 2025 | 6.26 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 2.83 Mn |
| Dec 31, 2024 | 2.83 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 12.57 Mn |
| Jun 30, 2024 | 12.57 Mn |
| Mar 31, 2024 | 12.27 Mn |
| Mar 31, 2024 | 12.27 Mn |
| Dec 31, 2023 | 10.65 Mn |
| Dec 31, 2023 | 10.65 Mn |